Skip to main content

Advertisement

Table 3 mRNA expression of studied genes in omental adipose tissue samples from endometrial cancer patients with different body mass index and obesity phenotype (real-time PCR)

From: Features of omental adipose tissue in endometrial cancer patients with ‘standard’ or ‘metabolically healthy’ obesity: associations with tumor process characteristics

Group mRNA expression value in units, 2−∆Ct (M ± m) BMI (M ± m)
UCP1 CYP19 Omentin PTEN
BMI <25.0 (9) 0.005 ± 0.0021 0.005 ± 0.002 0.383 ± 0.1522 1.029 ± 0.620IY 22.99 ± 0.38
BMI 25.0–29.9 (16) 0.022 ± 0.0081, I 0.008 ± 0.002 1.268 ± 0.476 3.400 ± 1.540 28.54 ± 0.26
BMI ≥30.0 (32) 0.919 ± 0.900I 0.010 ± 0.003 0.752 ± 0.318 4.920 ± 3.372 36.41 ± 1.11
BMI ≥25.0 (48)    0.932 ± 0.2652 4.473 ± 2.269IY  
SO (33) 0.019 ± 0.006II 0.007 ± 0.001 0.843 ± 0.300 4.242 ± 3.220 34.62 ± 1.11
MHO (14) 1.642 ± 1.620II 0.015 ± 0.007 1.161 ± 0.564 4.629 ± 1.780 31.65 ± 1.54
Endometrioid carcinomas (41) 0.592 ± 0.579III 0.008 ± 0.003 0.802 ± 0.284 2.208 ± 0.807Y 32.76 ± 1.13
Non-endometrioid carcinomas (14) 0.030 ± 0.013III 0.010 ± 0.002 0.960 ± 0.394 7.569 ± 5.885Y 29.61 ± 1.62
  1. A relative expression of each gene in samples was calculated using a 2−∆Ct formula (where Ct is cycle threshold), ∆Ct = Ct (target gene)—Ct (reference gene, SDHA, see “Methods and patients” section). Each of subgroups lacked an expression in some samples; mean values are given for cases with gene expression
  2. BMI body mass index, SO “standard” obesity, MHO “metabolically healthy” obesity. Numbers of cases are presented in brackets. UCP1—see notes to Table 2. CYP19 cytochrome 19, aromatase; Omentin—adipokine (fat tissue hormone initially discovered in a great omentum depot, see “Discussion” section); PTEN phosphatase (Phosphatase and tensin homolog) gene, whose mutation or lowered expression quite often is found in malignant tumors, including endometrial cancer (see “Discussion” section)
  3. Student’s t-test: p 1 0.05; p 2 0.06. Fischer’s exact test (by number of cases ≥ median for the whole group): I p 0.53; II p 0.50; III p 0.073 (in favor of non-endometrioid tumors due to one extremely different value in endometrioid carcinomas group); IY p 0.32 (Chi-square p 0.39); Y p 0.59